Zoetis (ZTS) Competitors

$76.62 -6.21 (-7.50%)

Closing price 03:59 PM Eastern

Extended Trading

$77.00 +0.38 (+0.49%)

As of 07:59 PM Eastern

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Bristol Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

How does Zoetis compare to Bristol Myers Squibb?

Zoetis (NYSE:ZTS) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Zoetis has a net margin of 27.80% compared to Bristol Myers Squibb's net margin of 15.01%. Zoetis' return on equity of 66.85% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Bristol Myers Squibb	15.01%	64.87%	13.16%

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.5%. Zoetis pays out 35.2% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

In the previous week, Zoetis had 4 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 49 mentions for Zoetis and 45 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.06 beat Zoetis' score of 0.36 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	23 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral
Bristol Myers Squibb	33 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive

Bristol Myers Squibb has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.39	$2.67B	$6.03	12.71
Bristol Myers Squibb	$48.19B	2.36	$7.05B	$3.56	15.62

Zoetis presently has a consensus price target of $141.25, suggesting a potential upside of 84.35%. Bristol Myers Squibb has a consensus price target of $61.31, suggesting a potential upside of 10.24%. Given Zoetis' stronger consensus rating and higher probable upside, analysts plainly believe Zoetis is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Zoetis beats Bristol Myers Squibb on 12 of the 19 factors compared between the two stocks.

How does Zoetis compare to Royalty Pharma?

Zoetis (NYSE:ZTS) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.39	$2.67B	$6.03	12.71
Royalty Pharma	$2.38B	12.53	$770.95M	$1.47	35.14

Zoetis presently has a consensus target price of $141.25, indicating a potential upside of 84.35%. Royalty Pharma has a consensus target price of $53.71, indicating a potential upside of 4.00%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Royalty Pharma	33.88%	29.25%	14.71%

92.8% of Zoetis shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 18.8% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zoetis has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.8%. Zoetis pays out 35.2% of its earnings in the form of a dividend. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years and Royalty Pharma has raised its dividend for 5 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Zoetis had 21 more articles in the media than Royalty Pharma. MarketBeat recorded 49 mentions for Zoetis and 28 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.71 beat Zoetis' score of 0.36 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	23 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral
Royalty Pharma	8 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zoetis beats Royalty Pharma on 12 of the 18 factors compared between the two stocks.

How does Zoetis compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Zoetis had 21 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 49 mentions for Zoetis and 28 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.63 beat Zoetis' score of 0.36 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	23 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.29	-$356.15M	-$0.02	N/A
Zoetis	$9.47B	3.39	$2.67B	$6.03	12.71

Jazz Pharmaceuticals currently has a consensus target price of $230.56, indicating a potential upside of 3.11%. Zoetis has a consensus target price of $141.25, indicating a potential upside of 84.35%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40

Jazz Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Zoetis	27.80%	66.85%	18.79%

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Zoetis beats Jazz Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Zoetis compare to Corcept Therapeutics?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Zoetis currently has a consensus target price of $141.25, indicating a potential upside of 84.35%. Corcept Therapeutics has a consensus target price of $74.67, indicating a potential upside of 45.83%. Given Zoetis' higher possible upside, research analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40
Corcept Therapeutics	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Zoetis has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.14%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Corcept Therapeutics	6.14%	7.40%	5.76%

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zoetis had 22 more articles in the media than Corcept Therapeutics. MarketBeat recorded 49 mentions for Zoetis and 27 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.00 beat Zoetis' score of 0.36 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	23 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral
Corcept Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.39	$2.67B	$6.03	12.71
Corcept Therapeutics	$761.41M	7.22	$99.65M	$0.35	146.29

Summary

Zoetis beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Zoetis compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Zoetis (NYSE:ZTS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Zoetis has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.99	-$38.55M	-$0.51	N/A
Zoetis	$9.47B	3.39	$2.67B	$6.03	12.71

Supernus Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Supernus Pharmaceuticals presently has a consensus target price of $62.17, indicating a potential upside of 25.92%. Zoetis has a consensus target price of $141.25, indicating a potential upside of 84.35%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40

Zoetis has a net margin of 27.80% compared to Supernus Pharmaceuticals' net margin of -3.74%. Zoetis' return on equity of 66.85% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Zoetis	27.80%	66.85%	18.79%

In the previous week, Zoetis had 34 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 49 mentions for Zoetis and 15 mentions for Supernus Pharmaceuticals. Zoetis' average media sentiment score of 0.36 beat Supernus Pharmaceuticals' score of 0.30 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zoetis	23 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral

92.8% of Zoetis shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Zoetis beats Supernus Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZTS vs. The Competition

Export

Metric	Zoetis	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$34.72B	$3.06B	$6.24B	$22.91B
Dividend Yield	2.56%	1.93%	2.78%	4.03%
P/E Ratio	12.71	12.26	17.70	25.76
Price / Sales	3.39	274.86	554.65	25.39
Price / Cash	10.95	55.41	27.81	19.21
Price / Book	10.14	4.16	9.77	4.65
Net Income	$2.67B	$72.19M	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-34.99%	3.32%	6.28%	3.95%
1 Year Performance	-52.10%	47.46%	41.80%	28.96%

Zoetis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZTS Zoetis	4.8543 of 5 stars	$76.62 -7.5%	$141.25 +84.3%	-48.2%	$34.72B	$9.47B	12.71	14,500	Earnings Report Analyst Forecast High Trading Volume
BMY Bristol Myers Squibb	4.8124 of 5 stars	$55.62 -1.0%	$61.31 +10.2%	+21.0%	$113.58B	$48.19B	15.62	32,500	Positive News Analyst Revision
RPRX Royalty Pharma	4.0975 of 5 stars	$51.65 +1.7%	$53.71 +4.0%	+53.2%	$29.79B	$2.44B	35.14	80	Earnings Report Analyst Upgrade
JAZZ Jazz Pharmaceuticals	3.2146 of 5 stars	$223.61 -1.0%	$230.56 +3.1%	+130.8%	$14.03B	$4.27B	N/A	2,890	Earnings Report
CORT Corcept Therapeutics	4.2703 of 5 stars	$51.20 -2.1%	$74.67 +45.8%	-25.6%	$5.50B	$769.10M	146.29	300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZTS) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Competitors

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

How does Zoetis compare to Bristol Myers Squibb?

Summary

How does Zoetis compare to Royalty Pharma?

Summary

How does Zoetis compare to Jazz Pharmaceuticals?

Summary

How does Zoetis compare to Corcept Therapeutics?

Summary

How does Zoetis compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zoetis (ZTS) Competitors

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

How does Zoetis compare to Bristol Myers Squibb?

Is ZTS or BMY more profitable?

Is ZTS or BMY a better dividend stock?

Which has more risk and volatility, ZTS or BMY?

Does the media prefer ZTS or BMY?

Which has stronger valuation and earnings, ZTS or BMY?

Do analysts prefer ZTS or BMY?

Do institutionals & insiders hold more shares of ZTS or BMY?

Summary

How does Zoetis compare to Royalty Pharma?

Which has higher earnings and valuation, ZTS or RPRX?

Do analysts prefer ZTS or RPRX?

Is ZTS or RPRX more profitable?

Do institutionals & insiders have more ownership in ZTS or RPRX?

Which has more volatility and risk, ZTS or RPRX?

Is ZTS or RPRX a better dividend stock?

Does the media prefer ZTS or RPRX?

Summary

How does Zoetis compare to Jazz Pharmaceuticals?

Does the media favor JAZZ or ZTS?

Which has higher earnings & valuation, JAZZ or ZTS?

Do analysts prefer JAZZ or ZTS?

Which has more volatility & risk, JAZZ or ZTS?

Is JAZZ or ZTS more profitable?

Do institutionals & insiders believe in JAZZ or ZTS?

Summary

How does Zoetis compare to Corcept Therapeutics?

Do analysts prefer ZTS or CORT?

Which has more risk & volatility, ZTS or CORT?

Is ZTS or CORT more profitable?

Do insiders and institutionals have more ownership in ZTS or CORT?

Does the media refer more to ZTS or CORT?

Which has stronger earnings and valuation, ZTS or CORT?

Summary

How does Zoetis compare to Supernus Pharmaceuticals?

Which has better valuation and earnings, SUPN or ZTS?

Which has more volatility and risk, SUPN or ZTS?

Do analysts prefer SUPN or ZTS?

Is SUPN or ZTS more profitable?

Does the media favor SUPN or ZTS?

Do institutionals and insiders believe in SUPN or ZTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools